Mylan: falls short of consensus in Q2.
(CercleFinance.com) - Before Wall Street opened on Wednesday Mylan disappointed, reporting Q2 results that were below the consensus.
While net income increased from 168.4 million dollars to 297 million dollars in one year, meaning respectively 33 cents and 55 cents per share, adjusted EPS came in 6 cents lower than analysts' expectations at 1.1 dollar.
The pharmaceutical laboratory's revenues reached 2.962 billion dollars, against the consensus of 3.022 billion dollars.
In addition, Mylan also significantly cut its FY forecasts, now expecting EPS of between 4.3 dollars and 4.7 dollars, compared to a previous target range of 5.15 dollars to 5.55 dollars. Meanwhile, revenues are expected to be between 11.5 billion dollars and 12.5 billion dollars, against a previous target range of 12.25 billion to 13.75 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
While net income increased from 168.4 million dollars to 297 million dollars in one year, meaning respectively 33 cents and 55 cents per share, adjusted EPS came in 6 cents lower than analysts' expectations at 1.1 dollar.
The pharmaceutical laboratory's revenues reached 2.962 billion dollars, against the consensus of 3.022 billion dollars.
In addition, Mylan also significantly cut its FY forecasts, now expecting EPS of between 4.3 dollars and 4.7 dollars, compared to a previous target range of 5.15 dollars to 5.55 dollars. Meanwhile, revenues are expected to be between 11.5 billion dollars and 12.5 billion dollars, against a previous target range of 12.25 billion to 13.75 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.